Vitamin D
Study Goal
The researchers aimed to determine whether vitamin D supplementation alters circulating long-chain ceramides and related metabolites involved in sphingolipid metabolism in humans.
Results Summary
The study conducted a post-hoc analysis of a randomized, placebo-controlled trial but did not explicitly report the outcomes regarding ceramide changes in the abstract.
Population
Overweight/obese African-American adults (n=70).
Effective Dosage
600, 2000, or 4000 IU/day of vitamin D.
Duration
Not specified in the abstract.
Interactions
None mentioned.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
vitamin D supplementation | neutral | circulating long-chain ceramides and related metabolites involved in sphingolipid metabolism | humans | - | would alter | #1 |
vitamin D supplementation | neutral | circulating long-chain ceramides and related metabolites involved in sphingolipid metabolism | overweight/obese African-Americans | - | would alter | #2 |
Sphingolipid metabolism plays a critical role in cell growth regulation, lipid regulation, neurodevelopment, type 2 diabetes, and cancer. Animal experiments suggest that vitamin D may be involved in sphingolipid metabolism regulation. In this study, we tested the hypothesis that vitamin D supplementation would alter circulating long-chain ceramides and related metabolites involved in sphingolipid metabolism in humans. We carried out a post-hoc analysis of a previously conducted randomized, placebo-controlled clinical trial in 70 overweight/obese African-Americans, who were randomly assigned into four groups of 600, 2000, 4000 IU/day of vitamin D